What does a nadir glucose of 2.9 mmol/L during a 72‑hour supervised fast and a good response to diazoxide indicate in a non‑diabetic patient?

Interpretation of a 2.9 mmol/L Nadir Glucose During 72-Hour Fast with Good Diazoxide Response

A nadir glucose of 2.9 mmol/L (approximately 52 mg/dL) during a supervised fast that responds well to diazoxide strongly suggests a confirmed diagnosis of insulinoma, as this glucose level falls within the diagnostic threshold and the positive diazoxide response indicates the hypoglycemia is mediated by suppressible insulin secretion from pancreatic beta cells.

Biochemical Significance of the 2.9 mmol/L Result

• A glucose level of 2.9 mmol/L (52 mg/dL) during a supervised fast meets the diagnostic criteria for pathologic hypoglycemia, as values below 55 mg/dL (approximately 3.0 mmol/L) warrant termination of the fast and biochemical evaluation. 1

• The diagnostic threshold for insulinoma is typically set at plasma glucose <40–45 mg/dL (2.2–2.5 mmol/L), though many experts consider glucose <55 mg/dL (3.0 mmol/L) sufficient when accompanied by inappropriate insulin secretion. 2, 3

• Your result of 2.9 mmol/L falls in the range where if insulin levels were >3 µIU/mL, C-peptide ≥0.6 ng/mL, and proinsulin ≥5 pmol/L were documented at this glucose nadir, the diagnosis of insulinoma is confirmed with 94.5% sensitivity within 48 hours of fasting. 3, 4

Clinical Significance of Diazoxide Response

• Diazoxide is the first-line medical therapy for managing hypoglycemia caused by insulinoma, as it directly suppresses insulin secretion from pancreatic beta cells by opening ATP-sensitive potassium channels. 3

• A good response to diazoxide confirms that the hypoglycemia is mediated by suppressible endogenous insulin secretion, which is the hallmark of insulinoma pathophysiology. 3

• This positive therapeutic response provides additional functional evidence supporting the diagnosis, as diazoxide would not be effective in hypoglycemia caused by non-insulin-mediated mechanisms (such as adrenal insufficiency, growth hormone deficiency, or non-islet cell tumors). 3

What This Result Pattern Indicates

• The combination of documented hypoglycemia (2.9 mmol/L) during a supervised fast plus diazoxide responsiveness creates a diagnostic pattern highly specific for insulinoma, assuming the critical biochemical markers (insulin >3 µIU/mL, C-peptide ≥0.6 ng/mL, proinsulin ≥5 pmol/L) were elevated at the time of hypoglycemia. 1, 3

• The fact that hypoglycemia occurred during a 72-hour fast (rather than post-prandially) further supports insulinoma as the diagnosis, since fasting-related neuroglycopenic symptoms are the classic presentation pattern for this tumor. 1

• Approximately 94.5% of insulinoma patients develop diagnostic hypoglycemia within 48 hours of fasting, so your result occurring within 72 hours is entirely consistent with this diagnosis. 4

Critical Next Steps in Management

• Proceed immediately to tumor localization imaging now that the biochemical diagnosis is established, starting with endoscopic ultrasound (EUS), which has 82–93% sensitivity for detecting pancreatic neuroendocrine tumors. 3

• Obtain multiphasic CT or MRI to assess for metastatic disease and provide anatomic detail for surgical planning. 3

• If non-invasive imaging fails to localize the tumor, selective arterial calcium stimulation with hepatic venous sampling achieves up to 90% success rate for localizing occult insulinomas. 3

• Continue diazoxide therapy to maintain glucose stability while proceeding with localization studies and surgical planning, as this prevents dangerous hypoglycemic episodes. 3

Definitive Treatment Pathway

• Surgical resection is the optimal curative treatment for locoregional insulinoma, with a 90% cure rate when the tumor is successfully removed. 3

• The surgical approach depends on tumor location: enucleation for peripheral lesions, distal pancreatectomy with splenic preservation for body/tail tumors, or pancreatoduodenectomy for head lesions that are deep or near the main pancreatic duct. 3

• Intraoperative ultrasound is mandatory during surgery, as it improves sensitivity to 92–97% for identifying small lesions that may have been missed on preoperative imaging. 3

Important Caveats

• Verify that a sulfonylurea screen was negative during the hypoglycemic episode to exclude factitious hypoglycemia from oral hypoglycemic agents. 1

• Confirm that C-peptide was elevated (≥0.6 ng/mL) at the time of hypoglycemia, as low C-peptide would indicate exogenous insulin administration rather than insulinoma. 1, 3

• Avoid somatostatin analogs (octreotide, lanreotide) for symptom management, as they can suppress counterregulatory hormones and precipitously worsen hypoglycemia, potentially causing fatal complications. 3